Literature DB >> 11683524

Postnatal development of presynaptic receptors that modulate noradrenaline release in mice.

V Schelb1, I Göbel, L Khairallah, H Zhou, S L Cox, A U Trendelenburg, L Hein, K Starke.   

Abstract

The objective of the study was to clarify the postnatal development of the following transmitter release-modulating receptors of noradrenergic neurons in mice: alpha2-adrenoceptors, muscarinic, opioid and cannabinoid receptors (inhibitory), beta-adrenoceptors and receptors for angiotensin II and bradykinin (facilitatory). Wildtype (NMRI) and in some cases alpha2A/D-adrenoceptor-deficient mice aged 1 day (P1) or 8-16 weeks (adults) were used. Hippocampal and occipito-parietal cortex slices and sympathetically innervated tissues (atria and vas deferens) were preincubated with [3H]-noradrenaline and then superfused and stimulated electrically. Stimulation led to distinct increases in tritium efflux which were abolished by tetrodotoxin or removal of calcium. Concentration-response curves of appropriate agonists and in the case of alpha2-autoreceptors antagonists were determined. For beta-adrenoceptors and angiotensin receptors, the interaction of agonists with antagonists was also examined. Results demonstrate that alpha2A/D-autoreceptors operate already at P1 whereas nonalpha2A/D-autoreceptors, presumably alpha2C, develop later. Of the various heteroreceptors, those of brain noradrenergic neurons (OP3 and ORL1) modulate the release of [3H]-noradrenaline at least as effectively at P1 as in adults. Those of peripheral sympathetic neurons (muscarinic, probably mainly M2, OP1, OP2, OP3, CB1, AT1 and B1), in contrast, operate less effectively or not at all at P1, with one exception: beta2-adrenoceptors increase the release of [3H]-noradrenaline (atria) to the same extent, irrespective of age. Overall, results indicate that brain and peripheral noradrenergic neurons release their transmitter already shortly after birth. Presynaptic receptor mechanisms mature differentially in the brain and the periphery. Moreover, the various presynaptic receptors differ in their postnatal development and may play differential roles at different ages.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683524     DOI: 10.1007/s002100100455

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  6 in total

1.  Differential targeting and function of alpha2A and alpha2C adrenergic receptor subtypes in cultured sympathetic neurons.

Authors:  Patricia C Brum; Carl M Hurt; Olga G Shcherbakova; Brian Kobilka; Timothy Angelotti
Journal:  Neuropharmacology       Date:  2006-06-05       Impact factor: 5.250

Review 2.  Genetic variation, β-blockers, and perioperative myocardial infarction.

Authors:  Peter Nagele; Stephen B Liggett
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

Review 3.  α(2)-adrenoceptors do not mediate neuroprotection in acute ischemic stroke in mice.

Authors:  Marc Brede; Stefan Braeuninger; Friederike Langhauser; Lutz Hein; Norbert Roewer; Guido Stoll; Christoph Kleinschnitz
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-27       Impact factor: 6.200

4.  α2-Adrenergic blockade mimics the enhancing effect of chronic stress on breast cancer progression.

Authors:  Donald M Lamkin; Ha Yeon Sung; Gyu Sik Yang; John M David; Jeffrey C Y Ma; Steve W Cole; Erica K Sloan
Journal:  Psychoneuroendocrinology       Date:  2014-10-12       Impact factor: 4.905

5.  Role of host β1- and β2-adrenergic receptors in a murine model of B16 melanoma: functional involvement of β3-adrenergic receptors.

Authors:  Federica Sereni; Massimo Dal Monte; Luca Filippi; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-19       Impact factor: 3.000

6.  Crosstalk between presynaptic angiotensin receptors, bradykinin receptors and alpha 2-autoreceptors in sympathetic neurons: a study in alpha 2-adrenoceptor-deficient mice.

Authors:  Anne-Ulrike Trendelenburg; Angelika Meyer; Werner Klebroff; Serafim Guimarães; Klaus Starke
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.